Cargando…

Efficacy and Safety of NaoShuanTong Capsule in the Treatment of Ischemic Stroke: A Meta-Analysis

Background: Ischemic stroke (IS) is a leading cause of death and long-term disability worldwide. The NaoShuanTong capsule (NSTC), a traditional Chinese patent medicine, has been extensively used in the treatment of stroke in China. However, the clinical efficacy and safety of this treatment has not...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hanlai, Xing, Yanwei, Chang, Jingling, Wang, Liqin, An, Na, Tian, Chao, Yuan, Mengchen, Yang, Xinyu, Shang, Hongcai, Gao, Ying, Gao, Yonghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797837/
https://www.ncbi.nlm.nih.gov/pubmed/31680944
http://dx.doi.org/10.3389/fphar.2019.01133
_version_ 1783459923155222528
author Zhang, Hanlai
Xing, Yanwei
Chang, Jingling
Wang, Liqin
An, Na
Tian, Chao
Yuan, Mengchen
Yang, Xinyu
Shang, Hongcai
Gao, Ying
Gao, Yonghong
author_facet Zhang, Hanlai
Xing, Yanwei
Chang, Jingling
Wang, Liqin
An, Na
Tian, Chao
Yuan, Mengchen
Yang, Xinyu
Shang, Hongcai
Gao, Ying
Gao, Yonghong
author_sort Zhang, Hanlai
collection PubMed
description Background: Ischemic stroke (IS) is a leading cause of death and long-term disability worldwide. The NaoShuanTong capsule (NSTC), a traditional Chinese patent medicine, has been extensively used in the treatment of stroke in China. However, the clinical efficacy and safety of this treatment has not been statistically and systematically verified by any comprehensive pooled analysis. We therefore performed a meta-analysis to evaluate the efficacy and safety of NSTC in the treatment of IS. Methods: Randomized controlled trials (RCTs) of NSTC in the treatment of IS conducted before September 2018 were retrieved from five databases, according to specific inclusion and exclusion criteria. Two investigators independently reviewed the included studies and extracted relevant data. The methodological quality of the included studies was assessed using criteria from the Cochrane Handbook, and analyzed using Review Manager 5.3 software. Results: Thirteen RCTs comprising a total of 1,360 participants were included in this study. NSTC was shown to significantly improve the overall response rate (OR = 3.04, 95% CI [1.76, 5.26], P < 0.00001), and neurological function (NSTC increased Modified Barthel Index (MD = 8.15, 95% CI [3.79, 12.52], P = 0.0005), Functional Independence Measure (MD = 29.61, 95% CI [10.11, 49.10], P = 0.003) and European Stroke Scale scores (MD = 8.51, 95% CI [7.00, 10.01], P = 0.03). In addition, NSTC significantly increased serum adiponectin level (MD = 0.66, 95% CI [0.23, 1.08], P = 0.002). Moreover, NSTC reduced atherosclerotic plaque area (MD = -2.24, 95% CI [-4.02, -0.46], P = 0.01) and intima-media thickness (MD = -0.09, 95% CI [-0.13, -0.05], P < 0.0001). However, there was no significant difference between NSTC treatment and conventional therapy with respect to Fugl-Meyer Assessment score (MD = 10.59, 95% CI [-1.78, 22.96], P = 0.09) or Crouse score (MD = -0.78, 95% CI [-1.79, -0.22], P = 0.13). Conclusions: The results of this meta-analysis showed that NSTC exhibits efficacy in the treatment of cerebral infarction. NSTC can improve the overall response rate and neurological function, increase blood adiponectin, reduce neurological deficits, and decrease atherosclerotic plaque area.
format Online
Article
Text
id pubmed-6797837
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-67978372019-11-01 Efficacy and Safety of NaoShuanTong Capsule in the Treatment of Ischemic Stroke: A Meta-Analysis Zhang, Hanlai Xing, Yanwei Chang, Jingling Wang, Liqin An, Na Tian, Chao Yuan, Mengchen Yang, Xinyu Shang, Hongcai Gao, Ying Gao, Yonghong Front Pharmacol Pharmacology Background: Ischemic stroke (IS) is a leading cause of death and long-term disability worldwide. The NaoShuanTong capsule (NSTC), a traditional Chinese patent medicine, has been extensively used in the treatment of stroke in China. However, the clinical efficacy and safety of this treatment has not been statistically and systematically verified by any comprehensive pooled analysis. We therefore performed a meta-analysis to evaluate the efficacy and safety of NSTC in the treatment of IS. Methods: Randomized controlled trials (RCTs) of NSTC in the treatment of IS conducted before September 2018 were retrieved from five databases, according to specific inclusion and exclusion criteria. Two investigators independently reviewed the included studies and extracted relevant data. The methodological quality of the included studies was assessed using criteria from the Cochrane Handbook, and analyzed using Review Manager 5.3 software. Results: Thirteen RCTs comprising a total of 1,360 participants were included in this study. NSTC was shown to significantly improve the overall response rate (OR = 3.04, 95% CI [1.76, 5.26], P < 0.00001), and neurological function (NSTC increased Modified Barthel Index (MD = 8.15, 95% CI [3.79, 12.52], P = 0.0005), Functional Independence Measure (MD = 29.61, 95% CI [10.11, 49.10], P = 0.003) and European Stroke Scale scores (MD = 8.51, 95% CI [7.00, 10.01], P = 0.03). In addition, NSTC significantly increased serum adiponectin level (MD = 0.66, 95% CI [0.23, 1.08], P = 0.002). Moreover, NSTC reduced atherosclerotic plaque area (MD = -2.24, 95% CI [-4.02, -0.46], P = 0.01) and intima-media thickness (MD = -0.09, 95% CI [-0.13, -0.05], P < 0.0001). However, there was no significant difference between NSTC treatment and conventional therapy with respect to Fugl-Meyer Assessment score (MD = 10.59, 95% CI [-1.78, 22.96], P = 0.09) or Crouse score (MD = -0.78, 95% CI [-1.79, -0.22], P = 0.13). Conclusions: The results of this meta-analysis showed that NSTC exhibits efficacy in the treatment of cerebral infarction. NSTC can improve the overall response rate and neurological function, increase blood adiponectin, reduce neurological deficits, and decrease atherosclerotic plaque area. Frontiers Media S.A. 2019-10-11 /pmc/articles/PMC6797837/ /pubmed/31680944 http://dx.doi.org/10.3389/fphar.2019.01133 Text en Copyright © 2019 Zhang, Xing, Chang, Wang, An, Tian, Yuan, Yang, Shang, Gao and Gao http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhang, Hanlai
Xing, Yanwei
Chang, Jingling
Wang, Liqin
An, Na
Tian, Chao
Yuan, Mengchen
Yang, Xinyu
Shang, Hongcai
Gao, Ying
Gao, Yonghong
Efficacy and Safety of NaoShuanTong Capsule in the Treatment of Ischemic Stroke: A Meta-Analysis
title Efficacy and Safety of NaoShuanTong Capsule in the Treatment of Ischemic Stroke: A Meta-Analysis
title_full Efficacy and Safety of NaoShuanTong Capsule in the Treatment of Ischemic Stroke: A Meta-Analysis
title_fullStr Efficacy and Safety of NaoShuanTong Capsule in the Treatment of Ischemic Stroke: A Meta-Analysis
title_full_unstemmed Efficacy and Safety of NaoShuanTong Capsule in the Treatment of Ischemic Stroke: A Meta-Analysis
title_short Efficacy and Safety of NaoShuanTong Capsule in the Treatment of Ischemic Stroke: A Meta-Analysis
title_sort efficacy and safety of naoshuantong capsule in the treatment of ischemic stroke: a meta-analysis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797837/
https://www.ncbi.nlm.nih.gov/pubmed/31680944
http://dx.doi.org/10.3389/fphar.2019.01133
work_keys_str_mv AT zhanghanlai efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis
AT xingyanwei efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis
AT changjingling efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis
AT wangliqin efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis
AT anna efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis
AT tianchao efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis
AT yuanmengchen efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis
AT yangxinyu efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis
AT shanghongcai efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis
AT gaoying efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis
AT gaoyonghong efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis